Skip to main content
. 2021 Feb 18;15(6):938–949. doi: 10.1093/ecco-jcc/jjab023

Figure 2.

Figure 2.

Proportion [90% CI] of patients in the safety analysis set with mucosal healing at Week 16 compared with baseline [Week 12 of TURANDOT]: [A] overall; [B] in patients who received placebo in TURANDOT; [C] in patients who received ontamalimab in TURANDOT. 90% CIs calculated using Wilson score test. Patients who were missing results for the endpoint were imputed as not meeting the endpoint. Treatment groups based on initial randomisation assignment. CI, confidence interval.